Eskelund CW, et al. - Through a retrospective cohort study of all 149 patients with progression/relapse of disease (POD), the researchers intended to determine the effectiveness of intensified frontline therapy in patients with mantle cell lymphoma (MCL). Patients who experienced POD after initial treatment were presented in the Nordic trials, MCL2 and MCL3. The significance of time to POD as both a prognostic and predictive marker was also confirmed. However, allogeneic stem cell transplant hadn't deleted the difference, but much-needed data on newer targeted agents for early progressors is required. Furthermore, R-bendamustine, although it has been administered in less aggressive states of disease, it was concluded superior to other more intensive combination chemo-immunotherapies.